IDEXX Laboratories Introduces Industry’s First Whipworm Antigen Test Capable of Detecting Adult Parasite
Next-generation intestinal parasite test detects more canine whipworm infections earlier than current diagnostic methods
WESTBROOK, Maine, July 08, 2014 — IDEXX Laboratories, Inc. (NASDAQ: IDXX) today announced the introduction of a breakthrough technology to detect more whipworm infections in dogs earlier than current diagnostic methods. As the industry’s first enzyme-linked immunosorbent assay (ELISA) for whipworm antigen detection, it is the only test capable of directly detecting the presence of an adult whipworm parasite.
Until now, diagnostic tests could only detect whipworm infections by the presence of eggs in the feces. Since it can take up to three months for an adult whipworm to produce eggs, infected dogs may go untreated for months. Data collected through IDEXX Reference Laboratories shows that the Whipworm Antigen ELISA can detect more than double the number of infections in dogs when the ELISA is run with traditional ova and parasite testing, allowing for earlier diagnosis, management and treatment.
“The Whipworm Antigen ELISA represents a leap forward in the ability to detect and treat this parasite in canine patients,” said Adam Potter, Product Manager, IDEXX. “At IDEXX we are committed to providing solutions for our customers to help deliver better care to pets, while creating strong relationships between veterinarians and pet owners.”
Veterinarians, including Dr. Alexandra Kintz-Konegger of K. Vet Animal Care in Greensburg, Pennsylvania, are already taking advantage of this new test as part of routine screening of dogs for intestinal parasites.
“We have had numerous samples test positive before clinical symptoms are evident,” Kintz-Konegger said. “This has allowed us to take a proactive stance and eliminate whipworms before shedding and contamination of the dog owner’s backyard. Clients are very appreciative of our preventive approach to medicine.”
In the United States, whipworm infections affect just over 2% of dogs in households and about 14% of dogs in animal shelters. Symptoms include the development of colitis, intermittent diarrhea, blood in the stool, weight loss, dehydration, anemia and occasionally death.
IDEXX customers are now able to order the Whipworm Antigen ELISA as part of the IDEXX Comprehensive Fecal Panel for canines beginning immediately. The IDEXX Comprehensive Fecal Panel also includes a fecal ova and parasite test and a Giardia antigen ELISA.
To learn more about the IDEXX Comprehensive Fecal Panel and the Whipworm Antigen ELISA, call 1-877-278-1470 or visit idexx.com/fecalantigen.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing livestock and poultry diagnostic tests and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,500 people and offers products to customers in more than 175 countries.
Note Regarding Forward-Looking Statements
This trade release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at www.sec.gov, at various SEC reference facilities in the United States and via the Company's website at www.idexx.com).
IDEXX Laboratories, Inc.